Peptide-binding induced inhibition of chemokine CXCL12
Hongyang Duan(Peking University), Yanlian Yang(National Center for Nanoscience and Technology)
Cited by 3
Related Papers
Apatinib Plus Toripalimab (Anti-PD1 Therapy) as Second-Line Therapy in Patients With Advanced Gastric or Esophagogastric Junction Cancer: Results From a Randomized, Open-Label Phase II Study
|The Oncologist|2024|10
Sensitive and dynamic CTCs measurement for prediction and monitoring of PD-1 therapy in GC/EGJC patients: Results from a pilot phase 2 study.
|Journal of Clinical Oncology|2021|0